Statin use and the risk of chronic kidney disease in patients with psoriasis: A nationwide cohort study in Taiwan

• Published in: PloS one Vol. 15; no. 8; p. e0237816
• Main Authors: Liu, Kwei-Lan, Tsai, Wen-Chien, Tu, Hung-Pin, Lee, Chih-Hung
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 25.08.2020; Public Library of Science (PLoS)
• Subjects: Age; Biology and Life Sciences; Chronic kidney failure; Cohort analysis; Complications and side effects; Confidence intervals; Dermatology; Diabetes; Drug dosages; Drug therapy; Generalized linear models; Health insurance; Health risks; Hospitals; Hyperlipidemia; Hypertension; Kidney diseases; Kidneys; Liver diseases; Medical diagnosis; Medicine; Medicine and Health Sciences; Patients; Population studies; Psoriasis; Risk; Risk assessment; Risk factors; Statins; Statistical models; Ulcers; Variables; Taiwan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0237816

Psoriasis is associated with hyperlipidemia. Few studies have examined the association among psoriasis, hyperlipidemia, and chronic kidney disease (CKD). It remains a topic of debate whether statin treatment for hyperlipidemia prevents the development of CKD in patients with psoriasis. We investigated whether there is an association among psoriasis, hyperlipidemia and CKD. If so, we asked whether statin treatment for hyperlipidemia reduces the risk of CKD in patients with psoriasis. A Taiwan nationwide population-based cohort study between 1997 and 2010 included 2,912 patients with psoriasis and 8,736 matched patients without psoriasis (1:3 propensity score matched according to age, sex, and region); 104,609 patients without psoriasis but with hyperlipidemia and 104,609 matched patients without psoriasis or hyperlipidemia (1:1). The hazard ratios, relative risks, and 95% confidence intervals were calculated using Cox proportional hazards model. Psoriasis significantly increased the risk of CKD (adjusted hazard ratio 2.48, 95% confidence interval 1.81-3.40), and so did hyperlipidemia (adjusted hazard ratio 2.93, 95% confidence interval 2.79-3.08). Compared to treatment without statins, statin treatment for hyperlipidemia reduced the risk of CKD in patients with psoriasis (adjusted relative risk 0.58, 95% confidence interval 0.55-0.62). As well as hyperlipidemia, psoriasis significantly increased the risk of CKD. Statin treatment for hyperlipidemia reduced the risk of CKD in patients with psoriasis.